2025-09-06 - Analysis Report
Okay, here's an analysis of Tempus AI (TEM), incorporating the data you provided. I'll follow your requested format with English, numbers first, then analysis.

**TEM Analysis (Unknown Company)**

**1. Relative Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (TEM):** 44.22%
*   **Cumulative Return (VOO):** 20.87%
*   **Absolute Spread:** 22.4
*   **Relative Spread:** 37.3 (within a range of Max: 102.9, Min: -25.4)

**Analysis:** TEM has significantly outperformed the S&P 500.  The relative spread of 37.3 indicates that TEM's outperformance is currently positioned in the upper range of its historical performance relative to the S&P 500, but does not represent a specific percentile of outperformance.

**Company Description:** Tempus AI is an *Unknown Company* company.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2023-2025  | 44.0% | 75.0% | 24.0% | -0.0 | 13.8 |

**Analysis:** TEM shows a high CAGR but also a very high MDD (Maximum Drawdown), indicating high volatility. The positive alpha of 24.0% suggests the stock has generated excess returns relative to its risk. The beta is essentially zero, suggesting little correlation with the market, though this might be unreliable due to the limited data period. The market cap is 13.8 billion.

**2. Recent Price Action**

*   **Current Price:** \$79.62
*   **Previous Close:** \$78.12
*   **Change:** 1.92%
*   **5-Day Moving Average:** \$77.56
*   **20-Day Moving Average:** \$73.60
*   **60-Day Moving Average:** \$66.00

**Analysis:** The price is above all moving averages, indicating an upward trend. The 1.92% increase suggests positive momentum.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3322 (Low Risk)
*   **RSI:** 58.30
*   **PPO:** 0.0334
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33)
*   **Recent Change in Relative Spread (20-day):** 2.0 (+) - Short-term Increase
*   **Expected Return (%):** NaN

**Analysis:** The MRI is in the low-risk range. The RSI is near the midpoint, suggesting neither overbought nor oversold conditions. The PPO is positive, supporting the upward trend. The Hybrid Signal suggests a strong buy, but advises caution due to the MRI. The increase in relative spread supports recent outperformance. Because the change between last price and previous close is relatively high (1.92%), it can be considered as a somewhat meaningful price movement. There is no data regarding the expected return.

**4. Recent News & Significant Events**

*   **Partnership with Northwestern Medicine:** Positive news, indicating adoption of Tempus AI's platform.
*   **Q2 Net Loss Improvement:** Suggests financial improvement.
*   **Integration of Tempus AI's Generative AI Co-Pilot (David):** Positive, showcasing product innovation and market adoption.
*   **Participation in Morgan Stanley Conference:** Increases visibility.
*   **HC Wainwright Initiates Tempus AI at Buy With \$90 Price Target:**  A strong positive signal from analysts.

**Analysis:** Recent news is predominantly positive, focusing on partnerships, product adoption, and analyst upgrades.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~2.15 on a 1-5 scale)
*   **Opinions:** 11
*   **Target Price (avg/high/low):** \$72.73 / \$90.00 / \$60.00

**Analysis:** Analyst consensus is positive, with a "Buy" rating. The average target price is lower than the current price, but the high target price is significantly higher. This suggests some analysts see substantial upside potential.

**5. Recent Earnings Analysis:**

| 날짜       | EPS    | 예상 EPS |
|------------|--------|----------|
| 2025-08-08 | -0.22  | -0.23    |
| 2025-05-06 | -0.24  | -0.26003 |
| 2025-02-24 | -0.18  | -0.15    |
| 2024-11-04 | -0.25  | -0.26608 |
| 2024-08-06 | -0.63  | -0.59    |

**Analysis:** The company is not yet profitable (negative EPS). However, the EPS has generally been beating expectations in recent quarters, which is a positive sign. The decreasing magnitude of negative EPS over time (except for one outlier) is also encouraging.

**6. Financial Information**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | \$0.31B | 61.99%        |
| 2025-03-31 | \$0.26B | 60.69%        |
| 2024-12-31 | \$0.20B | 60.83%        |
| 2024-09-30 | \$0.18B | 58.50%        |
| 2024-06-30 | \$0.17B | 45.50%        |

| Quarter    | Equity | ROE       |
|------------|---------|-----------|
| 2025-06-30 | \$0.31B | -13.84%   |
| 2025-03-31 | \$0.33B | -20.86%   |
| 2024-12-31 | \$0.06B | -23.10%   |
| 2024-09-30 | \$0.05B | -141.16%  |
| 2024-06-30 | \$0.10B | -562.04%  |

**Analysis:** Revenue is growing steadily. Profit margins are high and generally increasing, which is a very positive sign. However, the company has negative ROE, indicating that it is not yet generating profits on its equity. The significant fluctuations in ROE are likely due to the company's early stage and changing equity base.

**7. Overall Summary**

Tempus AI (TEM) presents a mixed picture.

**Positives:**

*   **Significant outperformance vs. S&P 500.**
*   **Strong revenue growth and high profit margins.**
*   **Positive analyst ratings and target price.**
*   **Beating EPS expectations.**
*   **Positive news flow regarding partnerships and product adoption.**

**Negatives:**

*   **Currently unprofitable (negative EPS and ROE).**
*   **High MDD indicating high volatility.**
*   **Average analyst target price is currently below the current price.**

**Conclusion:**

TEM appears to be a high-growth company with strong potential, but also significant risk. The high valuation (indicated by current price relative to average analyst target) suggests that the market has high expectations for future growth. The company's future profitability will be key to sustaining its current valuation. The low MRI indicates the market views the stock as low risk, which is likely due to its volatility and revenue growth. Investors should be aware of the potential for volatility and consider their risk tolerance before investing. Also, given the positive news flow, the recent price increase looks justified, but could mean TEM is currently overbought.
